Search PubMed⌕ Search

Biomedical subjects

G Tatra

Publications and source records attributed to G Tatra.

At least 37 records · Page 2Linked to original sources
PubMed1989

Platelet specific proteins (beta-thromboglobulin and platelet factor 4) in normal pregnancy and in pregnancy complicated by preeclampsia.

Pregnancy is accompanied by significant alterations of platelet function. Platelet activity can be determined by measurement of plasma levels of secreted platelet proteins. In this study we determined plasma levels of beta-Thromboglobulin (beta-TG) and Platelet Factor 4 (PF4) simultaneously in 35 women with uncomplicated pregnancy and in 15 patients with preeclampsia in third trimester of gestation. Additionally, PF4 plasma levels were measured using a commercially available Radio Immunoassay (RIA) and an Enzyme Immunoassay (EIA) simultaneously and values obtained were compared. Platelet count and creatinine were in the normal range in both groups; however, significantly higher levels of beta-TG (P less than 0.0005) and PF4 (P less than 0.0001) were found in case of preeclampsia. High levels of platelet proteins emphasize the active role of the platelets in the alterations of hemostasis in cases of preeclampsia.

Female↗
PubMed1989

Serum squamous cell carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls.

Squamous cell carcinoma antigen levels in 74 healthy volunteers, 57 patients with CIN and 91 patients with cervical carcinoma were determined by radioimmunoassay. 5.4% of healthy volunteers were above and all patients with CIN were below 3.0 ng/ml. 63.1% of 65 patients with primary squamous cell carcinoma, 1 out of 7 adenocarcinomas and 68.4% of 19 patients with recurrence of squamous cell carcinoma of the cervix had elevated SCC antigen levels. Elevated posttreatment levels carried a high risk factor of tumor persistence. Increases in SCC antigen levels during follow up usually signified recurrent carcinoma.

Aged↗
PubMed1989

Influence of delivery on plasminogen activator inhibitor activity.

Plasminogen activators initiate the fibrinolytic system by conversion of the proenzyme plasminogen to the active fibrin degrading enzyme plasmin. Plasminogen activator inhibitors inhibit the effects of both plasminogen activators. Uncomplicated pregnancies are accompanied by hypercoagulability and an increased risk of thromboembolic disease. Thrombosis is rare in the first trimester and most events are noted in the last trimester. Therefore, we studied the fibrinolytic system at the end of pregnancy and in the puerperium. Plasma concentrations of urokinase plasminogen activator (u-PA/competitive radioimmunoassay), tissue type plasminogen activator (t-PA/sandwich ELISA) and plasminogen activator inhibitor (PAI/functional assay) were determined in 44 women (age: 24.3 +/- 4.3 years) with normal pregnancy near term. Plasma samples were collected before the onset of labour and 1, 2, 3, 4 and 5 days after delivery. Compared with an age-matched non pregnant control group (8.3 +/- 3.94 U/ml) significantly increased PAI activity (12.13 +/- 4.79 U/ml - p less than 0.005) was measured before delivery with a subsequent significant decrease (8.13 +/- 1.97 U/ml) to normal values on day 1 after delivery; plasma u-PA and t-PA antigen levels remained unchanged. Placental weight and birth weight had no influence on plasma levels of both plasminogen activators.

Adult↗
PubMed1988

Beta lactoglobulin homologue placental protein 14 (PP14) in serum of patients with trophoblastic disease and non-trophoblastic gynecologic malignancy.

Serum levels of beta lactoglobulin homologue placental protein 14 (PP14) were measured by a sensitive radioimmunoassay in various trophoblastic diseases and non-trophoblastic gynecologic malignancies. While trace amounts of protein were detected in sera of non-pregnant subjects (22.3 +/- 13.7 micrograms/l), during first half of normal pregnancy a dramatic rise of serum-PP14 levels was demonstrable with a peak-value at 7th-10th week of gestation, followed by a decline thereafter. Serial determinations of PP14 have been performed in 31 patients with trophoblastic tumour (20 hydatidiform moles, 4 invasive moles and 7 choriocarcinomas). In patients with hydatidiform moles and invasive moles (273.5 +/- 106.5 micrograms/l and 162.2 +/- 109.6 micrograms/l) respective values before therapy were much exceeding the non-pregnant controls. After therapy there was a rapid decline of the serum-PP14 levels within two weeks. In patients with choriocarcinoma the PP14 values were moderately elevated (66.4 +/- 25.7 micrograms/l), and declined following the remission of disease. In 32 gynecological tumours (21 carcinomas of the cervix, 4 endometrial carcinomas, 5 ovarian carcinomas, 2 carcinomas of the vulva) the pretreatment levels were not different to normal controls.

Choriocarcinoma↗
PubMed1988

Serum PP12, PP14, SP1 and hCG values in the 28 days after the LH-surge in patients who do and do not conceive after artificial insemination or in vitro fertilization.

Serum levels of PP12 (somatomedin binding protein), PP14 (beta lactoglobulin homologue), Schwangerschaftsprotein 1 (SP1) and of human chorionic gonadotropin (hCG) were simultaneously measured in patients being treated for infertility in the 28 days after the LH-surge. PP14 levels were similar in the 14 days after the LH-surge in the patients who conceived when compared with those who did not and a high PP14 level was only indicative of pregnancy at 21 days after the LH-surge. hCG and SP1 levels behaved similarly in pregnant subjects. PP12 levels did not change significantly in the 28-days after the LH-surge.

Chorionic Gonadotropin↗
PubMed1988

Elevated tissue type plasminogen activator in human granulosa cells correlates with fertilizing capacity.

An increased production of plasminogen activators, able to convert plasminogen into plasmin, has been found in experiments in vivo on rat ovarian granulosa cells at the time of ovulation, indicating an involvement in follicular rupture. The granulosa cells of 49 follicles from 20 patients undergoing in-vitro fertilization were obtained by laparoscopy and tested for the content of urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA) and inhibitor of plasminogen activator (PAI). In the respective follicular fluids the concentrations of oestradiol (E2), progesterone (P) and testosterone (T) were determined and the levels of these enzymes and of the follicular steroid content were related to the fertilizing behaviour of the respective oocytes. Follicles containing oocytes which could be fertilized, revealed significantly higher follicular fluid E2 and P levels and significantly lower T levels than follicles with unfertilized oocytes. The respective granulosa cells of fertilized oocytes exhibited higher levels of t-PA compared to their unfertilized counterparts, whereas no significant difference occurred in the levels of u-PA and PAI. These data suggest that successful fertilization of human oocytes is associated with a high content of t-PA in granulosa cells and high E2 and P levels in the follicular fluid.

Adult↗
PubMed1988

[Comparative studies on the value of acute phase proteins and CA-125 for monitoring patients with ovarian cancer].

In a study of 71 patients with malignant ovarian tumors serum levels of CA-125, C-reactive protein (CRP), alpha-1-antitrypsin and coeruloplasmin were analysed. In contrast to the tumor-free group significantly higher values of CA-125, CRP and alpha-1-antitrypsin were found in the group with recurrent disease. However, the serum-concentrations of coeruloplasmin remained unchanged in both groups. In the group with progressive disease the median values of CA-125 were greater than 65 U/ml and of CRP greater than 12 micron/ml, respectively. The median serum concentrations of alpha-1-antitrypsin (2 to 4 mg/ml) and coeruloplasmin (150 to 600 ng/ml) did not reach their cut-off levels. Beside CA-125 the analysis of CRP and alpha-1-antitrypsin is an additional helpful procedure for the monitoring of patients with malignant ovarian tumors.

Acute-Phase Proteins↗
PubMed1988

Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.

Plasma concentrations of urokinase-type plasminogen activator (competitive radioimmunoassay), tissue-type plasminogen activator (sandwich enzyme-linked immunosorbent assay), and plasminogen activator inhibitor (functional assay) were measured in 17 women with endometrial cancer and 52 women with cervical carcinoma. Significantly increased plasma urokinase-type plasminogen activator antigen levels were found (11.3 +/- 4.7 ng/mL) in cervical cancer patients when compared with an age-matched control group (7.4 +/- 0.6 ng/mL). Women with endometrial cancer (9.9 +/- 2.0 ng/mL) showed a similar pattern of plasma urokinase-type plasminogen activator antigen levels. Patients with advanced cervical cancer (International Federation of Gynecology and Obstetrics stages III and IV) revealed higher plasma urokinase-type plasminogen activator antigen levels than those with stages I and II disease. Compared with an age-matched control group, neither carcinoma group showed elevated plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor.

Adenocarcinoma↗
PubMed1988

A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.

The serum concentrations of immunosuppressive acidic protein (IAP), CA 125, alpha-1-antitrypsin (AL-1-AT), C-reactive protein (CRP) and ceruloplasmin (COP) were determined in 63 patients with ovarian carcinoma (mean age 56.9 +/- 11.1 years). The threshold value of IAP was 640 micrograms/ml (means + 2SD), of CA 125 35 U/ml, of AL-1-AT 4 mg/ml, of CRP 12 micrograms/ml, and of COP 600 ng/ml. Eighty-three analyses of the patients with ovarian cancer coincided with tumor progression and 124 samples with remission. In women with progressive ovarian carcinoma the median IAP serum concentrations (799.3 +/- 292 micrograms/ml) were significantly increased as compared to the values of the healthy control group (48 volunteers, mean age 37.8 +/- 13.8 years; IAP 452.0 +/- 146.0 micrograms/ml). The median serum concentrations of IAP (799.3 +/- 292.2 micrograms/ml), CA 125 (933.8 +/- 1442.1 U/ml). AL-1-AT (3.8 +/- 8.7 mg/ml), CRP (31 +/- 39 micrograms/ml) were significantly elevated with progression as compared to remission (IAP 511.8 +/- 111.9 micrograms/ml, CA 125 18.4 +/- 14.4 U/ml, AL-1-AT 2.8 +/- 4.1 mg/ml, CRP 13 +/- 11 micrograms/ml). This was not the case with COP (509 +/- 761 vs. 466 +/- 106 ng/ml). A correlation between increased serum values and confirmed tumor progression was encountered in 65.1% of the patients for IAP, in 80.7% for CA 125 and in 34.9% for CRP and AL-1-AT. 98.8% false negative serum values were found for COP. Seven out of 16 and 4 out of 16 CA 125 negative samples showed right positive IAP and right positive CRP and AL-1-AT values, respectively. 88.7% of the IAP values, 92.7% of the CA 125 values, 71% of the AL-1-AT values, 93.5% of the CRP and 100% of the COP values were right negative. Our results indicate that the simultaneous determination of CA 125 and IAP enhance the efficiency of tumor monitoring in patients with ovarian cancer.

Antigens, Neoplasm↗
PubMed1987

[Immunosuppressive acid protein in pregnant females and in patients with ovarian cancer].

Serum levels of immunosuppressive acidic protein (IAP) were determined in 48 healthy controls (age: means = 37.8 +/- 13.8 years) and 72 pregnant women (age: means = 27.05 +/- 5.5 years). The mean value of IAP in pregnant women (345.3 +/- 94.4 micrograms/ml) was significantly lower than that of the healthy control group (P less than 0.0001; 452.0 +/- 95.0 micrograms/ml). Correlated to the clinical status were 207 IAP serum values of 63 patients with ovarian cancer (age: means = 56.9 +/- 11.1). The mean value of patients with tumor progression (means = 799.3 +/- 292.2 micrograms/ml) was significantly increased compared to those of patients in remission (means = 511.0 +/- 111.9 micrograms/ml) and the control group (means = 463 +/- 146.8 micrograms/ml; P less than 0.0001). However, no significant difference of the IAP levels was found between the group in remission and the healthy controls. With a threshold value of 640 micrograms/ml we found right-negative values in 88.7% and right-positive values in 65.1% during the follow-up of patients with ovarian cancer.

Adult↗
PubMed1987

The measurement of amniotic fluid immunoglobulins by laser nephelometry.

Using laser nephelometry IgG, IgA, and IgM levels in amniotic fluid samples from normal pregnancies were measured between 15 and 24 weeks and between 37 and 41 weeks gestation. Not enough samples between 25 and 36 were available for statistical analysis. IgG levels increased until the 20th and 24th weeks of gestation and declined significantly at term. However amniotic fluid IgM and IgA levels rose at term. Five samples of amniotic fluid associated with a fetus of abnormal karyotype were examined. In one case of Down's syndrome excessive IgA and IgM levels were found. In amniotic fluid obtained after intrauterine fetal death at term, very high levels of all three immunoglobulins were found.

Amniotic Fluid↗
PubMed1986

[Sex behavior following primary radiotherapy of cervix cancer].

57 women with invasive cervical carcinoma treated by primary irradiation were asked by means of a questionnaire about their partnership, especially about their sexual life. 9 women (15.7%) had no more sexual intercourse. 50% of those 48 patients who were sexually active also after the treatment had marked discomfort during coitus due to lack of lubrication. They reported pain caused by a short or narrow vagina less often (20.8%). Only 33.3% had their first intercourse 3 months after the irradiation, frequency of cohabitation was reduced in 68.4% of the patients. The reason for this was fear of recurrence of the cancer, fear of pain and lack of libido: 57.9% of the women mentioned reduced libido. Before irradiation 14% had no orgasm during the coitus, but 52% had none after treatment. The sexual life was not disturbed in those women who had been well informed about the consequences of the irradiation and who had their first intercourse soon after the therapy.

Adult↗
PubMed1986

[Recurrence of gynecologic malignancies after combined and primary radiotherapy. Incidence and lapse of time until the diagnosis is made].

A group of 1018 patients with gynecological malignancies after a combined or primary radiation therapy was studied for frequency and space of recurrence. In the first three years after therapy in cases with cervical cancer 95%, in cases with endometrial cancer 82% and in cases of ovarian cancer 98% of all recurrences were diagnosed. In cases of cancer of the vagina, the tube and vulva all recurrences were observed within the first three years. By results obtained it is put up for discussion to replace "five-years-rate" by "three-years-rate" in cases of gynecological malignancies with exception of mammary carcinoma. Thereby the value of a model of therapy could be realized earlier than hitherto.

Adenocarcinoma↗